A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD)
Study in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) whose Disease has Gotten Worse After Osermitinib Treatment
Sponsor: AstraZeneca AB
Enrolling: Male and Female Patients
IRB Number: AAAS5908
U.S. Govt. ID: NCT03944772
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to gain a better understanding of why some patients with non-small cell lung cancer and an epidermal growth factor receptor (EGFR-sensitizing mutation, fail first-line treatment with the drug osermitinib. Additionally, the purpose is to explore different drug therapies for patients whose cancer has progressed (gotten worse) after treatment with osermitinib, and to evaluate each therapy safety and how effective each is at treating cancer. Each patient will be evaluated for mutations that might have made them resistant to osermitinib. Patients with certain mutations will be placed in Groups A and B and will be assigned to an appropriate treatment option. Patients who do not meet eligibility criteria for the trial will be placed into an observational group where no study drugs will be received and no study procedures will be done.
This study is closed
Catherine Shu, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed advanced non-small cell lung cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator